Litcius/Paper detail

CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo

Handong Dan, Xinlan Lei, Xin Huang, Ning Ma, Yiqiao Xing, Yin Shen

2021Microvascular Research10 citationsDOI

Topics & Concepts

AngiogenesisNeovascularizationUmbilical veinVascular endothelial growth factorKinase insert domain receptorTyrosine kinaseIn vivoCancer researchVasculogenesisCell biologyVascular endothelial growth factor AIn vitroChemistryEndothelial stem cellPharmacologyBiologySignal transductionBiochemistryVEGF receptorsBiotechnologyRetinal Diseases and TreatmentsAngiogenesis and VEGF in CancerGlaucoma and retinal disorders
CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo | Litcius